




ANTICORPI MONOCLONALI





Fab

Fc

Ce sunt anticorpii monoclonali?





- Anticorpi identici, cu specificitate unică
- Aplicații în cercetare
- Utilizați pt. diagnostic
- Agenti terapeutici





Aplicații în imunologie


Imunofluorescentă /citometrie: mAb conjugati cu fluorocromi



Imunohistochimie/ELISA: mAb conjugati cu enzime



Antibody Therapy





- Cancer
- Infectious diseases
- Inflammatory diseases
- Autoimmune diseases
- Others
- Microbial diseases
- Microbial diseases



Antcorpi aprobați pentru uz clinic

- ± 80 mAb aprobați pentru uz clinic (dec 2019)



- 3863 imunoterapii în teste clinice (2018) în cancer

Dezvoltarea terapiei cu mAb

Nature Vol. 256 August 7 1975

Milstein &
Kohler
(Nobel)

Hybridoma



1891

1975

1984

1986

1997


1998

2002

2011

E. von Behring
P. Ehrlich


OKT3- first
antibody
approved by
FDA



humanized
Ab


- Trastuzumab ('98)

Checkpoint
inhibitor
Ipilimumab





Tehnologia hibridoamelor

G. Kohler & C. Millstein, Nature 256 (5517): 495-497 (1975) [Continuous Cultures of](#)



Screening


3



Subclonare

4

Expanding and freezing down the hybridomas



Cultura celulara


5

Antibody Validation

Purificare Ab

6

Ingeniería genética a anticorpilor



Nomenclature

-O-


-xi-

-zu-


-u-

-mab

Checkpoint inhibitors




Debloarea sistemului imun




Modul de acțiune al mAb



a Direct tumour cell killing



b Immune-mediated tumour cell killing



c Vascular and stromal cell ablation



Generația următoare

Anticorpi bispecifi

Anticorpi conjugati

Anticorpi cu functie Fc modi

Fragmente de Ab

‘Intracorpi’


nature

Subscribe

NEWS AND VIEWS · 18 NOVEMBER 2019

Trispecific antibodies offer a third way forward for anticancer immunotherapy

Immunotherapy approaches seek to boost immune responses against cancer. A single antibody engineered to recognize three targets shows promise, when tested in animals, in improving the ability of T cells to target cancer.



ANTIBODY COCKTAILS



fineart
america